Skip to main content
Erschienen in: Digestive Diseases and Sciences 5/2009

01.05.2009 | ORIGINAL ARTICLE

Crohn’s Disease in India: A Multicenter Study from a Country Where Tuberculosis Is Endemic

verfasst von: Kshaunish Das, Uday C. Ghoshal, Gopal K. Dhali, Jaya Benjamin, Vineet Ahuja, Govind K. Makharia

Erschienen in: Digestive Diseases and Sciences | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

Although Crohn’s disease is thought to be rare and intestinal tuberculosis common in India, Crohn’s disease is being reported more often. However, there is a lack of systematic study on Crohn’s disease from India. In this analysis of data from three inflammatory bowel disease clinics (two in northern India and one in eastern India), criteria for Crohn’s disease were applied retrospectively: (1) World Health Organization (WHO) criteria; or (2) compatible histology (European Crohn’s and Colitis Organization) or failure of response to 4–8 weeks of anti-tuberculosis therapy (Asia-Pacific guidelines); or (3) compatible macroscopic, radiologic, colonoscopic features (European Crohn’s and Colitis Organization). Others were classified as probable Crohn’s disease. The Montreal classification was used for disease phenotype. Age at onset and duration of symptoms (182 patients, 117 male) were 34.5 (±13.6; 7–73) years and 3.0 (±5.8; 0.1–36) years, respectively. Diarrhea (68%), abdominal pain (62%), and weight loss (57%) were common. The common intestinal complications were occult (27%) and overt (40%) gastrointestinal bleeding and obstruction (28%). There were 141 (78%) and 41 (22%) with definite and probable Crohn’s disease respectively. Of 147 (81%) available histopathology specimens (endoscopic biopsy in 110; 75%), 31 (21%) had granuloma. Seventy-one out of 166 (43%) had received anti-tuberculosis therapy in the past. Results from the Montreal classification were as follows: age at onset, A1:A2:A3 6%:64%:30%; location of disease, L1:L2:L3:L4 32%:41%:23%:4%, and disease behavior, B1:B2:B3 51%:24%:25%. Twenty-six (15%) and 31 (17%) patients had upper gastrointestinal and perianal modifiers. The drugs used were: aminosalicylates (128, 70%), steroids (76, 42%), azathioprine (53, 29%), methotrexate (4, 2%), and salazopyrine (14, 8%). Sixty-six (36%) patients underwent surgical treatment. We concluded that the phenotype of Crohn’s disease in India is very similar to that described in other regions of Asia and the West, except for a delay in diagnosis and a more complicated disease at diagnosis.
Literatur
2.
Zurück zum Zitat Ouyang Q, Tandon R, Goh KL, Ooi CJ, Ogata H, Fiocchi C. The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol. 2005;21:408–413.PubMed Ouyang Q, Tandon R, Goh KL, Ooi CJ, Ogata H, Fiocchi C. The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol. 2005;21:408–413.PubMed
5.
Zurück zum Zitat Probert CSJ, Jayanthi V, Pinder D, Wicks AC, Mayberry JF. Epidemiological study of ulcerative proctocolitis in Indian migrants and the indigenous population of Leicestershire. Gut. 1992;33:687–693. doi:10.1136/gut.33.5.687.PubMedCrossRef Probert CSJ, Jayanthi V, Pinder D, Wicks AC, Mayberry JF. Epidemiological study of ulcerative proctocolitis in Indian migrants and the indigenous population of Leicestershire. Gut. 1992;33:687–693. doi:10.​1136/​gut.​33.​5.​687.PubMedCrossRef
7.
Zurück zum Zitat Jayanthi V, Probert CSJ, Pinder D, Wicks ACB, Mayberry JF. Epidemiology of Crohn’s disease in Indian migrants and the indigenous population in Leicestershire. QJM. 1992;82:125–138.PubMed Jayanthi V, Probert CSJ, Pinder D, Wicks ACB, Mayberry JF. Epidemiology of Crohn’s disease in Indian migrants and the indigenous population in Leicestershire. QJM. 1992;82:125–138.PubMed
8.
Zurück zum Zitat Hilmi I, Tan YM, Goh KL. Crohn’s disease in adults: observations in a multiracial Asian population. World J Gastroenterol. 2006;12:1435–1438.PubMed Hilmi I, Tan YM, Goh KL. Crohn’s disease in adults: observations in a multiracial Asian population. World J Gastroenterol. 2006;12:1435–1438.PubMed
9.
Zurück zum Zitat Gupta RS, Chatterjee AK, Roy R, Ghosh BN. A review of the results of treatment of 44 cases of Crohn’s disease. Indian J Surg. 1962;24:787–805. Gupta RS, Chatterjee AK, Roy R, Ghosh BN. A review of the results of treatment of 44 cases of Crohn’s disease. Indian J Surg. 1962;24:787–805.
11.
Zurück zum Zitat Venugopalan S, Radhakrishnan S, Rajachandrasekharan R. Crohn’s disease (a study of 21 cases). Indian J Surg. 1980;42:388–396. Venugopalan S, Radhakrishnan S, Rajachandrasekharan R. Crohn’s disease (a study of 21 cases). Indian J Surg. 1980;42:388–396.
12.
Zurück zum Zitat Antia FP. Crohn’s conundrum in Indians. Indian J Gastroenterol. 1986;5:79–80.PubMed Antia FP. Crohn’s conundrum in Indians. Indian J Gastroenterol. 1986;5:79–80.PubMed
14.
Zurück zum Zitat Pai CG, Khandige GK. Is Crohn’s disease rare in India? Indian J Gastroenterol. 2000;19:17–20.PubMed Pai CG, Khandige GK. Is Crohn’s disease rare in India? Indian J Gastroenterol. 2000;19:17–20.PubMed
15.
Zurück zum Zitat Benjamin J, Makharia GK, Ahuja V, Kalaivani M, Joshi YK. Intestinal permeability and its association with the patient and disease characteristics in Crohn’s disease. World J Gastroenterol. 2008;14:1399–1405. doi:10.3748/wjg.14.1399.PubMedCrossRef Benjamin J, Makharia GK, Ahuja V, Kalaivani M, Joshi YK. Intestinal permeability and its association with the patient and disease characteristics in Crohn’s disease. World J Gastroenterol. 2008;14:1399–1405. doi:10.​3748/​wjg.​14.​1399.PubMedCrossRef
16.
17.
Zurück zum Zitat Ray G, Banerjee PK, Ghoshal UC, et al. Etiology and management of obscure gastrointestinal bleed—an appraisal from eastern India. Indian J Gastroenterol. 2001;20:90–93.PubMed Ray G, Banerjee PK, Ghoshal UC, et al. Etiology and management of obscure gastrointestinal bleed—an appraisal from eastern India. Indian J Gastroenterol. 2001;20:90–93.PubMed
21.
Zurück zum Zitat Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease in the last five decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13:481–489. doi:10.1002/ibd.20036.PubMedCrossRef Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease in the last five decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13:481–489. doi:10.​1002/​ibd.​20036.PubMedCrossRef
22.
Zurück zum Zitat Loftus EV, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinmeister AR. Crohn’s disease in Olmstead county, Minnesota, 1940–1993: Incidence, prevalence, and survival. Gastroenterology. 1998;114:1161–1168. doi:10.1016/S0016-5085(98)70421-4.PubMedCrossRef Loftus EV, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinmeister AR. Crohn’s disease in Olmstead county, Minnesota, 1940–1993: Incidence, prevalence, and survival. Gastroenterology. 1998;114:1161–1168. doi:10.​1016/​S0016-5085(98)70421-4.PubMedCrossRef
23.
Zurück zum Zitat Lapidus A, Bernell O, Hellers G, Persson PG, Löfberg R. Incidence of Crohn’s disease in Stockholm County 1955–1989. Gut. 1997;41:480–486.PubMed Lapidus A, Bernell O, Hellers G, Persson PG, Löfberg R. Incidence of Crohn’s disease in Stockholm County 1955–1989. Gut. 1997;41:480–486.PubMed
24.
Zurück zum Zitat Lapidus A. Crohn’s disease in Stockholm County during 1990–2001: An epidemiological update. World J Gastroenterol. 2006;12:75–81.PubMed Lapidus A. Crohn’s disease in Stockholm County during 1990–2001: An epidemiological update. World J Gastroenterol. 2006;12:75–81.PubMed
25.
Zurück zum Zitat Tsianos EV, Masalas CN, Merkouropoulos M, Dalekos GN, Logan RF. Incidence of inflammatory bowel disease in northwest Greece: rarity of Crohn’s disease in an area where ulcerative colitis is common. Gut. 1994;35:369–372. doi:10.1136/gut.35.3.369.PubMedCrossRef Tsianos EV, Masalas CN, Merkouropoulos M, Dalekos GN, Logan RF. Incidence of inflammatory bowel disease in northwest Greece: rarity of Crohn’s disease in an area where ulcerative colitis is common. Gut. 1994;35:369–372. doi:10.​1136/​gut.​35.​3.​369.PubMedCrossRef
26.
Zurück zum Zitat Mekjian HS, Switz DM, Melnyk CS, Rankin GB, Brooks RK. Clinical features and natural history of Crohn’s disease. Gastroenterology. 1979;77:898–906. Mekjian HS, Switz DM, Melnyk CS, Rankin GB, Brooks RK. Clinical features and natural history of Crohn’s disease. Gastroenterology. 1979;77:898–906.
27.
28.
Zurück zum Zitat Munkholm P, Binder V. Clinical features and natural history of Crohn’s disease. In: Sartor RB, Sandborn WJ, eds. Kirsner’s Inflammatory Bowel Diseases. 6th ed. Edinburgh: Saunders; 2004:289. Munkholm P, Binder V. Clinical features and natural history of Crohn’s disease. In: Sartor RB, Sandborn WJ, eds. Kirsner’s Inflammatory Bowel Diseases. 6th ed. Edinburgh: Saunders; 2004:289.
29.
Zurück zum Zitat Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi F, Belaiche J. Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49:777–782. doi:10.1136/gut.49.6.777.PubMedCrossRef Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi F, Belaiche J. Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49:777–782. doi:10.​1136/​gut.​49.​6.​777.PubMedCrossRef
30.
Zurück zum Zitat Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998;42:387–391.PubMed Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998;42:387–391.PubMed
31.
Zurück zum Zitat Chadha VK. Tuberculosis epidemiology in India: a review. Int J Tuberc Lung Dis. 2005;9:1072–1082.PubMed Chadha VK. Tuberculosis epidemiology in India: a review. Int J Tuberc Lung Dis. 2005;9:1072–1082.PubMed
32.
Zurück zum Zitat Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut. 1996;39:690–697. doi:10.1136/gut.39.5.690.PubMedCrossRef Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut. 1996;39:690–697. doi:10.​1136/​gut.​39.​5.​690.PubMedCrossRef
34.
Zurück zum Zitat Selby W, Pavli P, Crotty B, et al., Antibiotics in Crohn’s Disease Study Group. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine in Crohn’s disease. Gastroenterology. 2007;132:2313–2319. doi:10.1053/j.gastro.2007.03.031. Selby W, Pavli P, Crotty B, et al., Antibiotics in Crohn’s Disease Study Group. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine in Crohn’s disease. Gastroenterology. 2007;132:2313–2319. doi:10.​1053/​j.​gastro.​2007.​03.​031.
35.
Zurück zum Zitat Balasubramanian R, Nagarajan M, Balambal R, et al. Randomised controlled clinical trial of short course chemotherapy in abdominal tuberculosis: a 5-year report. Int J Tuberc Lung Dis. 1997;1:44–51.PubMed Balasubramanian R, Nagarajan M, Balambal R, et al. Randomised controlled clinical trial of short course chemotherapy in abdominal tuberculosis: a 5-year report. Int J Tuberc Lung Dis. 1997;1:44–51.PubMed
36.
Zurück zum Zitat Ghoshal UC, Ghoshal U, Singh H, Tiwari S. Anti-Saccharomyces cerevisiae antibody is not useful to differentiate between Crohn’s disease and intestinal tuberculosis in India. J Postgrad Med. 2007;53:166–170.PubMedCrossRef Ghoshal UC, Ghoshal U, Singh H, Tiwari S. Anti-Saccharomyces cerevisiae antibody is not useful to differentiate between Crohn’s disease and intestinal tuberculosis in India. J Postgrad Med. 2007;53:166–170.PubMedCrossRef
37.
Zurück zum Zitat Epstein D, Watermeyer G, Kirsch R. Review article: the diagnosis and management of Crohn’s disease in populations with high-risk rates for tuberculosis. Aliment Pharmacol Ther. 2007;25:1373–1388.PubMedCrossRef Epstein D, Watermeyer G, Kirsch R. Review article: the diagnosis and management of Crohn’s disease in populations with high-risk rates for tuberculosis. Aliment Pharmacol Ther. 2007;25:1373–1388.PubMedCrossRef
38.
Zurück zum Zitat Heresbach D, Alexandre JL, Branger B, et al., ABERMAD. Frequency and significance of granulomas in a cohort of incident cases of Crohn’s disease. Gut. 2005;54:215–222. doi:10.1136/gut.2004.041715. Heresbach D, Alexandre JL, Branger B, et al., ABERMAD. Frequency and significance of granulomas in a cohort of incident cases of Crohn’s disease. Gut. 2005;54:215–222. doi:10.​1136/​gut.​2004.​041715.
40.
Zurück zum Zitat Solberg IC, Vatn MH, Høie O, et al., Ibsen Study Group. Clinical course in Crohn’s disease: results of a Norwegian population-based 10-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430–1438. doi:10.1016/j.cgh.2007.09.002. Solberg IC, Vatn MH, Høie O, et al., Ibsen Study Group. Clinical course in Crohn’s disease: results of a Norwegian population-based 10-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430–1438. doi:10.​1016/​j.​cgh.​2007.​09.​002.
Metadaten
Titel
Crohn’s Disease in India: A Multicenter Study from a Country Where Tuberculosis Is Endemic
verfasst von
Kshaunish Das
Uday C. Ghoshal
Gopal K. Dhali
Jaya Benjamin
Vineet Ahuja
Govind K. Makharia
Publikationsdatum
01.05.2009
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 5/2009
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-008-0469-6

Weitere Artikel der Ausgabe 5/2009

Digestive Diseases and Sciences 5/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.